Compare prices and buy GHK-Cu + KPV Blend from 15 research peptide vendors - also called suppliers or sources. Updated daily.
GHK-Cu + KPV
A two-peptide research blend of GHK-Cu, the copper(II) complex of the tripeptide glycyl-histidyl-lysine, and KPV, the tripeptide Lys-Pro-Val from the C-terminus of alpha-melanocyte-stimulating hormone. GHK-Cu is studied in cell-culture models of collagen synthesis and tissue remodeling and KPV in preclinical models of inflammation, through unrelated mechanisms, and the combination has not been evaluated in a controlled human trial. It is also sold as "Beauty Blend". For research purposes only.
For research purposes only. Not medical advice.
The GHK-Cu and KPV blend combines two research tripeptides in one vial: GHK-Cu, the copper(II) complex of glycyl-histidyl-lysine, and KPV, the sequence Lys-Pro-Val. As a mixture it has no CAS number of its own. The components carry 89030-95-5 and 67727-97-3, and a certificate of analysis should report each one separately.
Most vials indexed here are 60 mg, holding 50 mg of GHK-Cu and 10 mg of KPV. A smaller group is 70 mg, with the KPV doubled to 20 mg. The 60 mg form is KLOW without BPC-157 and TB-500.
GHK-Cu delivers Cu2+ to tissue, where copper is a cofactor for connective-tissue enzymes such as lysyl oxidase, which crosslinks collagen. In cell culture it upregulates collagen and decorin synthesis and modulates matrix metalloproteinase activity.
KPV is residues 11-13 of alpha-melanocyte-stimulating hormone but lacks the His-Phe-Arg-Trp core that melanocortin-receptor binding depends on, so it does not share the pigmentation activity of alpha-MSH or Melanotan II. Cell and rodent work describes it entering intestinal and immune cells through the PepT1 transporter and suppressing NF-kB activation, lowering pro-inflammatory cytokine output. The most cited study, from Didier Merlin's group (Gastroenterology, 2008), used mouse colitis models.
Both mechanisms rest on cell-culture and animal work. The peptides derive from unrelated parent molecules and act on unrelated targets, so the pairing is a market convention rather than a pharmacological one. A Europe PMC search on October 20, 2026 for GHK-Cu, GHK or copper tripeptide with KPV or Lys-Pro-Val returned three review articles and one unrelated data paper, and no study of the combination.
PeptideScouter records a blend's size as the vial total, the convention the KLOW page explains. GHK-Cu is most of the mass in both sizes and the cheaper component per milligram, so the blend's figure mostly reflects the copper peptide, and the 70 mg vial, with twice the KPV, does not compare directly with the 60 mg one.
Neither component is an FDA-approved drug. Nominations to FDA's compounding lists are made per substance, and the two records have split.
Committee votes are advisory, and the list changes only through notice-and-comment rulemaking. GHK-Cu is also a skincare ingredient, labelled under its INCI name, copper tripeptide-1. FDA classes a product as a cosmetic or a drug by intended use, so the same ingredient in a product marketed to affect the structure or function of the body is regulated as a drug.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
Two research tripeptides in one vial: GHK-Cu, the copper(II) complex of glycyl-histidyl-lysine, and KPV, the sequence Lys-Pro-Val from the C-terminus of alpha-melanocyte-stimulating hormone. Most vials indexed here are 60 mg, holding 50 mg of GHK-Cu and 10 mg of KPV, and some are 70 mg, with the KPV raised to 20 mg. The blend has no CAS number of its own because it is a mixture. Its components carry 89030-95-5 for GHK-Cu and 67727-97-3 for KPV. Beauty Blend is a vendor trade name for it, and material sold by research peptide vendors is offered for laboratory use only, not for human consumption.
No published study of the pair turned up. A Europe PMC search on October 20, 2026 for GHK-Cu, GHK or copper tripeptide together with KPV or Lys-Pro-Val returned three review articles and one unrelated data paper, and no study that tested the two together. Each peptide has its own preclinical literature: GHK-Cu in cell-culture work on copper delivery, collagen synthesis and matrix remodeling, and KPV in cell and rodent work on PepT1 uptake and NF-kB suppression in intestinal inflammation. The pairing is a market convention rather than a pharmacological one.
Neither is an FDA-approved drug, and their compounding records differ. FDA placed injectable GHK-Cu and KPV in Category 2 of its 503A interim policy on September 29, 2023, and announced both removals on April 15, 2026, effective seven days later, after the nominations were withdrawn. KPV then went to the Pharmacy Compounding Advisory Committee, which voted 8-6 with one abstention on July 23, 2026 to recommend adding it to the 503A bulks list. GHK-Cu for routes other than injection is listed in Category 1, under evaluation, on FDA's May 14, 2026 list, and FDA intends to consult the committee on GHK-Cu before the end of February 2027. Committee votes are advisory, and the list changes only through notice-and-comment rulemaking.
That depends on how a product is marketed. GHK-Cu appears on skincare labels under its INCI name, copper tripeptide-1, and FDA decides whether a product is a cosmetic or a drug by its intended use. A product intended to affect the structure or any function of the body meets the drug definition in the Federal Food, Drug, and Cosmetic Act, whatever the ingredient. GHK-Cu also sits in FDA's compounding categories, with injectable and other routes on separate tracks. None of this applies to research-grade material, which vendors offer for laboratory use only.
PeptideScouter records a blend's size as the total peptide content of the vial. GHK-Cu is about 83 percent of a 60 mg vial and about 71 percent of a 70 mg vial by mass, and it is by a wide margin the cheaper of the two components per milligram, so the blend's figure mostly reflects the copper peptide. The 70 mg vial holds twice the KPV, the costlier component, so the two sizes are not directly comparable with each other either. The price table on this page lists the blend's own listings, and each component's live prices are on its own page.
GHK-Cu + KPV Blend is sold by 15 research peptide vendors indexed on PeptideScouter, with 20 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
13 of the 15 indexed vendors currently have GHK-Cu + KPV Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Flawless Compounds currently lists GHK-Cu + KPV Blend at $0.69/mg, the lowest listed price across 15 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.49/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 15 vendors listing GHK-Cu + KPV Blend publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $0.55/mg listed to $0.49/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
GHK-Cu + KPV Blend ranges from $0.55/mg to $1.22/mg across 20 listings from 15 research peptide vendors, normalized to USD per milligram and refreshed daily.
15 research peptide vendors currently list GHK-Cu + KPV Blend on PeptideScouter, with 13 in stock right now. We track 20 listings across size and kit variants.
